Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861406 · ClinicalTrials.gov registry record · Phase 1
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT00861406: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00861406 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861406, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients that had Stage II or Stage III melanoma and are free of the disease. The safety and tolerability of this drug combination will also be studied. Researchers also want to collect long-term follow-up information.
Interventions
- DRUG Pegylated Interferon-Alfa 2b (PEG Intron)
- DRUG GP-100 Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-03-10 |
| Est. Completion | 2017-02-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00861406
The ClinicalTrials.gov registry entry for NCT00861406 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pegylated Interferon-Alfa 2b (PEG Intron) is the first listed.
NCT00861406 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00861406 about?
NCT00861406 is a clinical study titled "Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine". The goal of this clinical research study is to find the best dosing schedule of a combined treatment of PEG Intron® (pegylated Interferon-alfa 2b) plus a peptide vaccine (gp100) that may help improve immune response in patients that had Stage II or Stage III melanoma and are free of the disease. The...
What is the current status of trial NCT00861406?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2009-03-10. Estimated completion is 2017-02-24.
What interventions are being tested in trial NCT00861406?
The interventions under investigation include: Pegylated Interferon-Alfa 2b (PEG Intron) (DRUG), GP-100 Peptide Vaccine (DRUG).
Who is sponsoring clinical trial NCT00861406?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.